




ZIOPHARM Oncology, Inc.  
Investor Relations Department  
One First Ave., Parris Building, # 34  
Navy Yard Plaza  
Boston, MA 02199  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

#### NASDAQ: ZIOP

Last Trade:	4.45
Trade Time:	4:00 PM ET Mar 16, 2018
Change:	0.08  (+1.831%)
Day Range	4.32 - 4.47
52-Week Range	3.33 - 7.88
Volume	1,254,314


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse portfolio of treatments for people with cancer and graft-versus-host -disease. Our focus is on the development of cell and viral -therapies using a suite of technologies that employing novel gene expression, control and cell technologies to deliver safe, effective and scalable therapies.

... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- Mar 1, 2018*  
[Ziopharm Oncology Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update](#)
- Feb 13, 2018*  
[Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference Call on March 1](#)
- Feb 12, 2018*  
[Ziopharm Oncology Presents Data on Very Rapid Production of CAR T Cells at Keystone Symposia Emerging Cellular Therapies: T Cells and Beyond](#)
- Feb 6, 2018*  
[Ziopharm Oncology Addresses Rumors and Stock Volatility, Affirms 2018 Guidance](#)
- Jan 9, 2018*  
[Ziopharm Oncology Provides Update on Standout Technologies during the 36th Annual J.P. Morgan Healthcare Conference](#)

### Financials [\[ View all \]](#)

- Mar 1, 2018*  
[Annual Report \(10-K\)](#)
- Apr 28, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 6, 2017*  
[Quarterly Report \(10-Q\)](#)
- Jul 31, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 1, 2017*  
[Quarterly Report \(10-Q\)](#)